Form 4: Anterix Inc. Executive Granted Stock Options
SEC Form 4 Filing
Anterix Inc.'s Chief Regulatory and Communications Officer, Christopher Guttman-McCabe, was granted stock options for 67,774 shares on January 16, 2025.
Summary
- Christopher Guttman-McCabe, Chief Regulatory and Communications Officer at Anterix Inc., was granted stock options for 67,774 shares.
- The options have an exercise price of $27.83 per share.
- The options vest in three equal annual installments starting on January 16, 2025, contingent on continued service.
- The options expire on January 16, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the options is dependent on the future performance of Anterix Inc.'s stock price.
- If the executive leaves the company before the options fully vest, they may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next three years, contingent on the executive's continued service.
Industry Context
Stock options are a common form of executive compensation in the technology and telecommunications industries, used to attract and retain talent.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation across various industries, particularly in technology and growth-oriented companies.
- The vesting schedule of three years is also a common practice to ensure long-term commitment from executives.
- The specific number of options and exercise price would be benchmarked against similar roles and company performance within the telecommunications sector.
Stakeholder Impact
- Shareholders may view this positively as it incentivizes management to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/16/2025 | Date of the stock option grant and the start of the vesting period. |
| 01/21/2025 | Date the form was signed by the Attorney-in-Fact. |
| 01/16/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, Anterix Inc., ATEX, vesting, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.